Human serum albumin as the carrier to fabricate STING-activating peptide nanovaccine for antitumor immunotherapy.

"Declaration of competing interest ☑ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper."

"This work is supported by the Joint Funds for the Innovation of Science and Technology of Fujian Province (Grant No. 2020Y9046), the Scientific Foundation of Fuzhou Municipal Health commission (Grant No. 2022-S-wt3), the 10.13039/501100001809National Natural Science Foundation of China (Grant No. 22274023), the Fujian Provincial Clinical Research Center for Hepatobiliary and Pancreatic Cancers (Grant No. 2020Y2013), and the Major Scientific Research Program for Young and Middle-aged Health Professionals of Fujian Province (Grant No. 2021ZQNZD013 and 2021ZQNZD014). Aixian Zheng: Formal analysis, Funding acquisition, Investigation, Methodology, Writing – original draft. Zhaoyu Ning: Formal analysis, Investigation, Methodology. Xiaorong Wang: Formal analysis, Investigation, Methodology. Zhenli Li: Methodology, Software. Yupeng Sun: Formal analysis, Funding acquisition, Investigation. Ming Wu: Investigation, Methodology. Da Zhang: Investigation, Methodology. Xiaolong Liu: Funding acquisition, Project administration, Supervision, Writing – review & editing. Jianwu Chen: Conceptualization, Project administration, Supervision. Yongyi Zeng: Funding acquisition, Project administration, Supervision."